Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 10:5:163.
doi: 10.3389/fphar.2014.00163. eCollection 2014.

ABC transporters in CSCs membranes as a novel target for treating tumor relapse

Affiliations
Review

ABC transporters in CSCs membranes as a novel target for treating tumor relapse

Laura Zinzi et al. Front Pharmacol. .

Abstract

CSCs are responsible for the high rate of recurrence and chemoresistance of different types of cancer. The current antineoplastic agents able to inhibit bulk replicating cancer cells and radiation treatment are not efficacious toward CSCs since this subpopulation has several intrinsic mechanisms of resistance. Among these mechanisms, the expression of ATP-Binding Cassette (ABC) transporters family and the activation of different signaling pathways (such as Wnt/β-catenin signaling, Hedgehog, Notch, Akt/PKB) are reported. Therefore, considering ABC transporters expression on CSCs membranes, compounds able to modulate MDR could induce cytotoxicity in these cells disclosing an exciting and alternative strategy for targeting CSCs in tumor therapy. The next challenge in the cure of cancer relapse may be a multimodal strategy, an approach where specific CSCs targeting drugs exert simultaneously the ability to circumvent tumor drug resistance (ABC transporters modulation) and cytotoxic activity toward CSCs and the corresponding differentiated tumor cells. The efficacy of suggested multimodal strategy could be probed by using several scaffolds active toward MDR pumps on CSCs isolated by tumor specimens.

Keywords: CSCs; HTS; MDR; P-gp; TICs markers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cancer stem cells targeting strategies.
Chart 1
Chart 1
Natural HIF inhibitors.
Chart 2
Chart 2
Porcupine and Tankyrase inhibitors.
Chart 3
Chart 3
Hypoxia Activated Prodrugs (HAP).
Chart 4
Chart 4
Agents targeting CSCs.

References

    1. Abdul-Ghani R., Serra V., Györffy B., Jürchott K., Solf A., Schäfer R. (2006). The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 25, 1743–1752 10.1038/sj.onc.1209201 - DOI - PubMed
    1. Al-Hajj M., Wicha M. S., Benito-Hernandez A., Morrison S. J., Clarke M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100, 3983–3988 10.1073/pnas.0530291100 - DOI - PMC - PubMed
    1. Alvero A. B., Montagna M. K., Holmberg J. C., Craveiro V., Brown D., Mor G. (2011). Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol. Cancer Ther. 10, 1385–1393 10.1158/1535-7163.MCT-11-0023 - DOI - PMC - PubMed
    1. An Y., Ongkeko W. M. (2009). ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin. Drug Metab. Toxicol. 5, 1529–1542 10.1517/17425250903228834 - DOI - PubMed
    1. Baccelli I., Trumpp A. (2012). The evolving concept of cancer and metastasis stem cells. J. Cell Biol. 198, 281–293 10.1083/jcb.201202014 - DOI - PMC - PubMed

LinkOut - more resources